חיפוש במאגר התרופות הישראלי

CNS Stimulant. Methylphenidate HCl 18/27/36/54 mg.
PR Tabs 30/90 X 18/27/36/54 mg
Ped. pts. 6 to 12 years of age: start 18 mg once/d, range: 18 mg to 54 mg once/d. Pts 13 to 17 years of age: start 18 mg once/d, range: 18 mg to 72 mg once/d (not to exceed 2 mg/kg/d). Adults 18 to 65 years of age: start 18 or 36 mg once/d, range: 18 mg to 72 mg once/d.
Tmt.of Attention Deficit Hyperactivity Disorder (ADHD). in pts aged 6 to 65 years old.
C/I:  Hypersens• Anxiety, tension • Agitation • Hyperthyroidism • Pre-existing cardiovasc. dis. incl. sev. hypertens, angina, arterial occlusive dis; HF, haemodynamically signif.congenital heart dis., cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels) • During tmt. with monoamine oxidase (MAO) inhibitors, or within a min. of 2 weeks of discontinuing those drugs, due to risk of hypertensive crisis • Glaucoma • Phaeochromocytoma • Diagnosis or family hist. of Tourette's syndr.

Selective Immunosuppressive Agents. Teriflunomide 14 mg.
FC Tab  28 X 14 mg
one tablet (14 mg) per day
Tmt. of adults with relapsing-remitting multiple sclerosis, in order to reduce the freq. of relapses and to delay the progress. of physical disability.
C/I:  Hypersens. Pts with severe hep. impairm. (Child-Pugh class C). Pregn. women, or women of childbearing potential who are not using reliable contraception during tmt and thereafter as long as its plasma levels are above 0.02 mg/l. Pregn. must be excluded before start of treatment. Breast-feeding women. Pts with sev. immunodeficiency states, e.g. AIDS. Pts with signif. impaired bone marrow function or signif. anaemia, leukopenia, neutropenia or thrombocytopenia. Pts with sev. active infect. until resolution. Pts with sev renal impairm. undergoing dialysis, because insuff. clin. exper. is available. Pts with sev. hypoproteinaemia, e.g. in nephrotic syndr.

Iron Chelating Agent. Deferasirox 125/250/500 mg.
Disp. tabs, 30/60 X125, 250, 500 mg
For patients > 2 years old:
For pts regularly receiving blood transf. - 20 mg /kg BW.
• For pts. who do not regularly receive blood transf. - 10 mg /kg BW
Max daily dosage is: • 40 mg /kgBW for pts regularly receiving blood transf.
• 20 mg /kgBW for adlts not regularly receiving blood transfusions.
• 10 mg /kg BW for childr. < 18 years not regularly receiving blood transf.
For chron. iron overload due to blood transf. (transfusional haemosiderosis) in adult and chilr > 2 years. Also for chron. iron overload in pts with non-transfusion-dependent thalassemia syndr. aged  >10 years. Chelation ther. should only be initiated when liver iron concentration [LIC]≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 μg/l. LIC is the preferred method of iron overload determination and should be used wherever available.
C/I:Hypersens., mod. or sev. kidney dis.,conc. use of another chelating agent 

Anti-Androgen. Enzalutamide 40 mg.
FC caps 120 X 40 mg
160 mg enzalutamide (4 caps.) as a sgle daily dose.
tmt of adult men with high-risk non-metast. castration resist. prostate cancer (CRPC). – tmt. of adult men with metast. CRPC who are asymptom. or mildly symptom. after failure of androgen deprivation ther. in whom chemother. is not yet clinically indicated.- tmt. of adult men with metast. CRPC whose dis. has progressed on or after docetaxel ther. - tmt of adult men with metast. hormone-sensitive prostate cancer (mHSPC) in combin. with androgen deprivation ther.
As monother. or in combin. with androgen deprivation ther. for the tmt of adult men with high risk biochemical recurrent (BCR) non-metast. hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiother.
C/I: hypersens. Women who are or may become pregn.

Selective Immunosuppressants. Teriflunomide 14 mg.
FC Tabs 28 X 14 mg
One tab/d.
Tmt of adults with relapsing remitting forms of Multiple Sclerosis (MS) to reduce the freq. of clin. relapses and to delay the progress. of physical disability.
C/I: Hypersens./Pts with sev hepatic impairm. (Child-Pugh class C)/
Pregn. women, or women of childbearing potent. who are not using reliable contraception during tmt with teriflunomide and thereafter as long as its plasma levels are above 0.02 mg/l .Pregn. must be excluded before start of tmt/
Breast-feeding women /Pts with sev. immunodeficiency states, e.g. acquired immunodeficiency syndrome (AIDS)/ Pts with signif. impaired bone marrow function or signif. anaemia, leukopenia, neutropenia or thrombocytopenia/Pts with sev. active infection until resolution/  Pts with sev. renal impairm. undergoing dialysis, because insuff. clin. experience is available in this patient group/Pts with sev. hypoproteinaemia, e.g. in nephrotic syndr.

LMWH. Enoxaparin 100 mg/ml, Enoxaparin 150 mg/ml.
Pre-filled syr. with sol. for SC inj./IV bolus during hemodialysis.
2/10 X 12,000 IU (120 mg / 0.8 ml )
2/10 X 15,000 IU (150 mg/1 ml )
Dosage to be indiv. adjust. by physic. according to weight and med. condit. of ptt
• Prophylaxis of venous thromboembolic dis. in moder. and high -risk surgical pts, in particular those undergoing orthopaedic or gral surgery incl. cancer surgery. • Prophylaxis of venous thromboembolic dis. in pts with an acute illness (such as acute HF, resp. insuff., sev. infections or rheumatic dis.) and reduced mobility at incr. risk of venous thromboembolism. • Tmt. of deep vein thrombosis(DVT) and pulmonary embolism (PE), excl. PE likely to require thrombolytic ther. or surgery. • Prevention of thrombus formation in extra corporeal circul. during haemodialysis. • Acute coronary syndr: Tmt. of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combin. with oral acetylsalicylic acid. – Tmt. of acute ST-segment elevation myocardial infarction (STEMI) incl. pts to be managed medic. or with subsequent percutaneous coronary intervention (PCI).
C/I: Hypersens. incl to heparin and deriv./ Hist. of immune mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies/ Active clin. signif. bleeding and conditions with a high risk of haemorrhage, incl. recent haemorrhagic stroke, GI ulcer, presence of malign. neoplasm at high risk of bleeding, recent brain, spinal or ophthalmic surgery, known or suspect. oesophageal varices, arteriovenous malform., vasc. aneurysms or major intraspinal or intracerebral vasc. abnormalities/ Spinal or epidural anaesthesia or loco-regional anaesthesia when enoxaparin sodium is used for tmt. in the previous 24 hs.